Trial | NCT00563355  Report issue

Title

A Study to Evaluate Whether Correction of Anemia Using Recombinant Human Erythropoietin Reduces the Progression of Atherosclerosis and Cardiac Hypertrophy in Pre-dialysis Chronic Kidney Disease Patients
A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    epoetin ...

  • Study Participants

    66
The primary aim of the study is to evaluate the effects of correction of anemia using erythropoietin on the progression of atherosclerosis and cardiac muscle thickening in patients with chronic kidney disease
Study Started
Feb 28
2001
Study Completion
Nov 30
2003
Last Update
Jun 16
2011
Estimate

Drug erythropoietin

Criteria 

Inclusion Criteria:

Patients with chronic renal failure with serum creatinine between 150umol/L and 800umol/L and at the same time Hb
Patients with regression line of 1/serum creatinine versus time showing that they may not require dialysis within the coming 12 months
Patients below the age of 75

Exclusion Criteria:

Patients with valvular heart disease/congenital heart disease
Patients with ischemic heart disease/history of myocardial infarction/coronary artery bypass surgery
Patients with history of heart failure
Patients with regression line of 1/serum creatinine versus time showing that the estimated date of end stage renal disease is within 12 months
Patients with thalassemic trait or haemoglobinopathies
Patients with underlying haematological malignancies
Patients with active bleeding
Patients with uncorrected iron or other vitamins deficiencies
Patients with poor general condition
No Results Posted